Treating or preventing nephrogenic diabetes insipidus
In certain embodiments, the disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a AMPK activator to a subject in need thereof, wherein In certain embodiments, the AMPK activator is metformin or salt thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.
1. A method of preventing nephrogenic diabetes insipidus comprising administering an effective amount of an AMPK activator in combination with lithium to a subject in need thereof.
2. The method of claim 1 , wherein the AMPK activator is metformin or salt thereof.
3. The method of claim 1 , wherein the AMPK activator is 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside or salt thereof.
4. The method of claim 1 , wherein the AMPK activator is 4-hydroxy-3-(2′-hydroxy-[1,1′-biphenyl]-4-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-5-carbonitrile or salt thereof.
5. The method of claim 1 , wherein the AMPK activator is 5-(3-(4-(2-(4-Fluorophenyl)ethoxy)phenyl)propyl)furan-2-carboxylic acid or salt thereof.
6. The method of claim 1 , wherein the AMPK activator is O2′,O3′,O5′-tri-acetyl-N6-(3-hydroxylaniline)adenosine or salt thereof.
7. The method of claim 1 , wherein the AMPK activator is 2-chloro-5-[[5-[[5-(4,5-Dimethyl-2-nitrophenyl)-2-furanyl]methylene]-4,5-dihydro-4-ox-o-2-thiazolyl]amino]benzoic acid or salts thereof.
8. A method of treating nephrogenic diabetes insipidus comprising administering an effective amount of an AMPK activator in combination with lithium to a subject in need thereof.
9. The method of claim 8 , wherein the AMPK activator is metformin or salt thereof.
10. The method of claim 8 , wherein the AMPK activator is 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside or salt thereof.
11. The method of claim 8 , wherein the AMPK activator is 4-hydroxy-3-(2′-hydroxy-[1,1′-biphenyl]-4-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-5-carbonitrile or salt thereof.
12. The method of claim 8 , wherein the AMPK activator is 5-(3-(4-(2-(4-Fluorophenyl)ethoxy)phenyl)propyl)furan-2-carboxylic acid or salt thereof.
13. The method of claim 8 , wherein the AMPK activator is O2′,O3′,O5′-tri-acetyl-N6-(3-hydroxylaniline)adenosine or salt thereof.
14. The method of claim 8 , wherein the AMPK activator is 2-chloro-5-[[5-[[5-(4,5-Dimethyl-2-nitrophenyl)-2-furanyl]methylene]-4,5-dihydro-4-ox-o-2-thiazolyl]amino]benzoic acid or salts thereof.